5 burning questions for an orphan drug CEO
This article was originally published in Scrip
Executive Summary
Legislation introduced since the 1980s and 1990s to incentivise the development of new treatments for rare diseases is paying off (about a third of new drug approvals are now for orphan medicines), but there is also growing concern among payers that some orphan drug prices may be unsustainable. The recent pricing of BioMarin Pharmaceutical's Vimizim at an estimated annual cost per patient of $380k drew attention to the issue once again (scripintelligence.com, 18 February 2014).
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.